Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. - Wikidata - wikimedia - TriplyDB

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

http://www.wikidata.org/entity/Q50653679

about

Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia Recombinant factor VIIa as haemostatic therapy in advanced liver disease Changing Concepts of Cirrhotic Coagulopathy.Medical and endoscopic management of gastric varices.Procoagulant therapeutics in liver disease: a critique and clinical rationale.[Therapy with blood products].Venous thromboembolism in cirrhosis.'The TIPSing Point'.Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.Management of variceal and nonvariceal upper gastrointestinal bleeding in patients with cirrhosis.Management of acute variceal bleeding.Treatment of portal hypertension Clinical pharmacology of portal hypertension.Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis Variceal bleeding: consensus meeting report from the Brazilian Society of Hepatology.Acute esophageal variceal bleeding: Current strategies and new perspectives Prevention and management of gastroesophageal varices in cirrhosis.Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document".Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study.Update of endoscopy in liver disease: more than just treating varices.The international normalized ratio does not reflect bleeding risk in esophageal variceal hemorrhage.Use of Activated Recombinant Factor VII in Severe Bleeding - Evidence for Efficacy and Safety in Trauma, Postpartum Hemorrhage, Cardiac Surgery, and Gastrointestinal Bleeding.Improving survival in decompensated cirrhosis Management by the intensivist of gastrointestinal bleeding in adults and children.The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework.Prognostic indicators of survival in patients with compensated and decompensated cirrhosis.Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.Management of varices in cirrhosis.Portal hypertension in children: expert pediatric opinion on the report of the Baveno v Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension.Blood component support in acquired coagulopathic conditions: is there a method to the madness?Liver disease, coagulopathies and transfusion therapy Off-label use of recombinant factor VIIa in two tertiary hospitals in Queensland.Management of varices in patients with cirrhosis.The coagulation system in patients with end-stage liver disease.Managing complications in cirrhotic patients Gastrointestinal endoscopy in the cirrhotic patient.

P2860

Q24201292-FF19BD2D-58F7-4E2C-9E96-FB9E3572532D Q24201303-EAA249F4-D98C-4256-BC73-7273BE8CD99B Q24236583-76C3610F-3449-4060-BC59-DAF31C998687 Q24236772-179C927D-2EC9-409A-9262-15FB20F070EC Q24245204-C0664F5A-40FE-44AC-AD53-4C5573E07551 Q26822857-D29882F1-193C-4D53-8071-84550F3F010A Q30275544-59DFECB0-DEA0-4500-B72B-EE50FA087383 Q30425322-F0E72E16-3328-455C-B5EB-A1ED7C23289B Q30458618-047CF9D2-4D61-4882-A6DB-0FA136D914F1 Q33429614-6E91AB93-65E7-4639-8D69-19B3374A1029 Q33724083-B453AB76-F577-4058-BA41-4A36A296AA2F Q33754092-22186CBE-9D68-4323-A074-B24997615AB6 Q33756657-7AC0A795-17DE-460E-8E40-00E12EB9C553 Q33937329-F5AAEB1B-8225-485E-ABFE-0995D3ED3BE9 Q34036903-3EEA28D7-65F1-4354-9BD1-566889A72103 Q34265176-4D59C563-D540-439D-B15F-748E249B6AA6 Q34399357-4D84F675-D9F0-4EF3-9F36-C856F7B3B7FC Q34472516-8C41A163-5D03-4897-ADDD-9F6FC92D03BE Q34622605-5CC7A456-D303-444B-864D-803E4199EFA0 Q34625821-38B61AAD-96E7-4AED-87F0-ABABDABD6501 Q34638216-AD8138E6-1C98-4D56-B156-02D50EDB96EE Q34654443-FC34A1A6-0426-42E5-9BD8-D6153BEA3F98 Q34786006-5580DE82-8426-4760-991D-D22C6C73D7DB Q35738416-1719B161-3C8C-45F5-BEFB-028DD5432E5E Q35973813-F69EEE96-7CCA-434A-AB14-B081DA355B2D Q35998366-D8BF0A5D-B7D2-418F-A631-011DC03E1A95 Q36090423-98E089DF-C358-4C79-A4A2-560754A15588 Q36478606-E7544B32-152A-4922-8BCB-1C1CCFA27625 Q36537350-83ACF9F4-37D2-4BE8-99E0-98CF51F2E50C Q37019451-500C74AF-6AAF-4616-B1AC-672C37F33E29 Q37489472-FC861D65-4464-4902-941F-2E995F71AE0E Q37832507-30CB1AC2-1280-4753-AF45-E5DEAB86786D Q37992682-3FFB2CEC-3302-45A5-9312-AC1AC852F155 Q37999723-BDB96BF6-57C6-426D-AEC1-4B070228BCAE Q38051476-2BAD49C0-54A7-4EB5-997E-BECB31710B4C Q38058551-4121CDC8-89EF-424B-BB6A-8D75D67E75FC Q38094881-6C6AB1BC-C6D9-403A-B75D-F4815190C048 Q38295874-DF901105-5339-4D53-9590-8B44A354785F Q38344890-E1F30DC0-149F-4F24-A708-E25A37F41084 Q38476069-62BC0FE7-734B-4E57-B48A-1D9F8DB133C9

P2860

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

http://www.wikidata.org/entity/Q50653679

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Recombinant factor VIIa for va ...... randomized, controlled trial.

@en

Recombinant factor VIIa for va ...... randomized, controlled trial.

@nl

type

label

Recombinant factor VIIa for va ...... randomized, controlled trial.

@en

Recombinant factor VIIa for va ...... randomized, controlled trial.

@nl

prefLabel

Recombinant factor VIIa for va ...... randomized, controlled trial.

@en

Recombinant factor VIIa for va ...... randomized, controlled trial.

@nl

P1433

Q50653679-EA01F850-CEAE-4135-B3B9-020BFC14B40F

P1476

Q50653679-3FDFD4BC-527C-4335-A8C3-25F9810C9D6D

P2093

Q50653679-088D9022-07EA-42C0-A78F-1228FAB712D6

Q50653679-0EF3F4BD-BA42-46BB-84C3-A5B7CBC58624

Q50653679-2008281B-DAC4-4D81-A2E2-E489FA19C3B1

Q50653679-34E62719-673F-4518-B8B5-A79A4D9D6BAD

Q50653679-3B949B5B-C334-411F-BA0F-6E7A02253956

Q50653679-773717A0-7336-40BF-A018-252BD8AD5701

Q50653679-8DB1535C-B14C-4A1F-BFF5-A28C66CD5BCC

Q50653679-AB3086ED-FA21-4991-B9CE-ADB388325450

Q50653679-BBE838A1-F12E-4F0B-9742-91B350C57112

Q50653679-C1A70622-40A6-42B2-BAD3-54D498ECCB15

P2860

Q50653679-02C3E90D-9750-480B-A71F-3627FAF22F0C

Q50653679-3BDA6E9D-7112-476B-B664-1BAE0A3BB395

Q50653679-4B3269E7-03ED-451B-A319-5402A7CB761A

Q50653679-8512097C-9A25-4376-92A0-F551849FC769

Q50653679-9AA643DF-6A2D-4F26-B6D7-C44B8986FBCE

Q50653679-9B7D0755-3C20-44BC-B837-8628B3AE8B8B

Q50653679-C4492CFE-4E77-44A6-90C7-4156D41E4D29

Q50653679-CD91DFF4-3E37-45A2-9B82-90F2F20F3A1F

Q50653679-D0CCBC4B-A95D-4EC6-92F5-56CC2E54C659

Q50653679-DB382A24-C329-4809-BD17-01950DCDC6F9

P304

Q50653679-945D0022-53F3-4A4F-BC30-04645B7556E3

P31

Q50653679-A68D2908-F501-4A30-A22F-D52BFFB7302F

P356

Q50653679-B246996B-CC0C-4B19-9B46-92275CB1735B

P407

Q50653679-AEE31A65-4C33-46CA-9AB5-7FF5E9A5EB8D

P433

Q50653679-D79DA363-897E-4512-8A3D-C73A08B3B051

P478

Q50653679-67A3E17A-8EA3-4808-AB4A-F107599F60CF

P577

Q50653679-77143EB7-593A-4D41-A12B-33A30853252F

P5875

Q50653679-6166BC34-CC84-48D4-AC66-9783FFDF4EC6

P698

Q50653679-F051BC8F-F814-4492-9F35-6B2155EA7DB5

P356

P1433

P1476

Recombinant factor VIIa for va ...... randomized, controlled trial.

@en

P2093

Agustín Albillos

http://www.w3.org/2001/XMLSchema#string

Didier Lebrec

http://www.w3.org/2001/XMLSchema#string

Dominique Thabut

http://www.w3.org/2001/XMLSchema#string

Flemming Bendtsen

http://www.w3.org/2001/XMLSchema#string

Gennaro D'Amico

http://www.w3.org/2001/XMLSchema#string

International Study Group on rFVIIa in UGI Hemorrhage

http://www.w3.org/2001/XMLSchema#string

Jaime Bosch

http://www.w3.org/2001/XMLSchema#string

Julien Massard

http://www.w3.org/2001/XMLSchema#string

Julius Spicak

http://www.w3.org/2001/XMLSchema#string

Nicolas Carbonell

http://www.w3.org/2001/XMLSchema#string

P2860

Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis.

High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.

Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis.

Gastroesophageal variceal hemorrhage.

Recombinant activated factor VII for acute intracerebral hemorrhage.

Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis.

Improving prognosis following a first variceal haemorrhage over four decades

Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage

Improved patient survival after acute variceal bleeding: a multicenter, cohort study.

Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators.

P304

1604-1614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22216

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5459943

http://www.w3.org/2001/XMLSchema#string

P698

18393319

http://www.w3.org/2001/XMLSchema#string